Contribute Try STAT+ Today

Initially, plans for the huge clinical trial were proceeding apace.

After months of groundwork, about 1,000 different sites were identified in 42 countries. And a key meeting involving trial investigators and coordinators from around the U.S. and Europe was scheduled to review protocols and compare notes. But then the coronavirus struck.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If seasonal flu kills up to 650,000 people per year and medical systems can handle that, the disruption from COVID-19 should be manageable with proactive steps that governments around the world are already initiating. The interest in COVID-19 is so high, there will be tremendous resources allocated to come up with medical solutions, like the Apollo program to land on the moon. This will mitigate the impact. All of the worst case estimates assume that we passively let it run its course without these major new medical initiatives.

Comments are closed.